ZA200609838B - Method to reduce hepatotoxicity of Fas-mediated apoptosis-inducing agents - Google Patents

Method to reduce hepatotoxicity of Fas-mediated apoptosis-inducing agents

Info

Publication number
ZA200609838B
ZA200609838B ZA200609838A ZA200609838A ZA200609838B ZA 200609838 B ZA200609838 B ZA 200609838B ZA 200609838 A ZA200609838 A ZA 200609838A ZA 200609838 A ZA200609838 A ZA 200609838A ZA 200609838 B ZA200609838 B ZA 200609838B
Authority
ZA
South Africa
Prior art keywords
fas
inducing agents
mediated apoptosis
reduce hepatotoxicity
hepatotoxicity
Prior art date
Application number
ZA200609838A
Other languages
English (en)
Inventor
Dupuis Marc
Goedkoop Renu
Demotz Stuphane
Original Assignee
Apoxis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoxis Sa filed Critical Apoxis Sa
Publication of ZA200609838B publication Critical patent/ZA200609838B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200609838A 2004-06-04 2006-11-24 Method to reduce hepatotoxicity of Fas-mediated apoptosis-inducing agents ZA200609838B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57739904P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
ZA200609838B true ZA200609838B (en) 2008-02-27

Family

ID=34968590

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609838A ZA200609838B (en) 2004-06-04 2006-11-24 Method to reduce hepatotoxicity of Fas-mediated apoptosis-inducing agents

Country Status (11)

Country Link
US (1) US20080003226A1 (xx)
EP (1) EP1750763A1 (xx)
JP (1) JP2008501666A (xx)
CN (1) CN1976721A (xx)
AU (1) AU2005249236A1 (xx)
BR (1) BRPI0511683A (xx)
CA (1) CA2566975A1 (xx)
IL (1) IL179358A0 (xx)
MX (1) MXPA06014077A (xx)
WO (1) WO2005117966A1 (xx)
ZA (1) ZA200609838B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046247A1 (en) * 1999-02-05 2000-08-10 Merck & Co., Inc. Methods of use for dna molecules encoding m68, a tnf receptor-related protein
EP1203819A3 (en) * 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use

Also Published As

Publication number Publication date
AU2005249236A1 (en) 2005-12-15
US20080003226A1 (en) 2008-01-03
EP1750763A1 (en) 2007-02-14
CA2566975A1 (en) 2005-12-15
JP2008501666A (ja) 2008-01-24
MXPA06014077A (es) 2007-02-15
WO2005117966A1 (en) 2005-12-15
CN1976721A (zh) 2007-06-06
IL179358A0 (en) 2007-03-08
BRPI0511683A (pt) 2008-01-08

Similar Documents

Publication Publication Date Title
IL191990A0 (en) Methods of using cd40 binding agents
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
IL187361A0 (en) Methods of purifying tigecycline
IL182693A0 (en) Methods of preparing indazole compounds
PT1778618E (pt) Síntese de trietilenotetraminas
IL185757A0 (en) Methods of decreasing calcifcation
EP1874731A4 (en) CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
ZA200702977B (en) Methods of preparing indazole compounds
PL1837028T3 (pl) Sposób usuwania leukocytów
HK1161122A1 (en) Use of 24-norudca 24-norudca
HK1145083A1 (en) Purification of fluorinated alcohols
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
EP1899375A4 (en) NEW METHOD FOR THE PURIFICATION OF LACTOFERRIN
ZA200802893B (en) Purification of water
EP1711484A4 (en) SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES
IL172276A0 (en) Cross-reference to related application
EP2037916A4 (en) PURE TRITOQUALINE ISOMERS
ZA200609838B (en) Method to reduce hepatotoxicity of Fas-mediated apoptosis-inducing agents
IL183378A0 (en) Methods of making pravastatin sodium
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
GB0523031D0 (en) Enhancement of morphine analgesia by s(-)-norketamine
GB0401475D0 (en) Method of signalling
GB0504333D0 (en) Treatment of cytokine dysregulation
SI1812422T1 (sl) Kristalna oblika irbesartana
ZA200708109B (en) Method of peptide synthesis